KEYNOTE studies

KEYNOTE studies are a series of clinical trials conducted by Merck to evaluate the effectiveness and safety of their cancer immunotherapy, pembrolizumab. These studies involve patients with various types of cancer and assess how well the treatment works alone or with other therapies. They help determine whether pembrolizumab can improve survival and control cancer growth, leading to potential approval for new uses. Overall, KEYNOTE studies advance our understanding of how immune-based treatments can help combat different cancers.